Application of artemisia rupestris extract in preparation of medicine for preventing and treating lung diseases

Abstract

The invention relates to application of an Artemisia rupestris extract in preparation of medicines for preventing and treating lung diseases. According to the application of the artemisia rupestris extract in preparation of the medicine for preventing and treating the lung diseases, the artemisia rupestris extract is prepared by taking artemisia rupestris as a raw material, and the crude drug concentration is 20-110 mg / mL. The artemisia rupestris extract contains chemical components such as sesquiterpenoids, flavonoids, organic acids and phenylpropanoids. The medicine is a veterinary medicine. The lung diseases comprise allergic pneumonia, pulmonary fibrosis or diseases caused by injury of other lung tissues. The dosage form of the medicine for preventing and treating the lung diseases is a pharmaceutically acceptable dosage form. The pharmaceutically acceptable dosage form is oral liquid, powder, tablets, granules, capsules, pills, syrup, suspension or emulsion. The application defines the prevention and treatment effect of the Artemisia rupestris extract on lung diseases. During application, the artemisia rupestris extract is small in dosage and high in curative effect, and the weight of livestock and poultry can be greatly reduced due to the fact that lung tissue is damaged.

Description

Technical Field

[0001] The present application relates to a new use of Artemisia annua, and specifically to the use of an Artemisia annua extract in the preparation of a medicine for preventing and treating lung diseases. Background Art

[0002] Artemisia annua, also known as Xinjiang Artemisia annua, is the whole herb of Artemisia sphaerocephala of the Artemisia genus of the Asteraceae family. Traditional Chinese medicines with similar names to Artemisia annua include Artemisia sphaerocephala on snow (Ranunculaceae), Artemisia sphaerocephala on earth (Asteraceae), etc., but although the names are similar, their types, ingredients and therapeutic effects are different from those of the Artemisia annua in this application.

[0003] Artemisia striata, also known as Xinjiang Artemisia striata, has the effects of dispelling wind and relieving exterior symptoms, strengthening the stomach and eliminating accumulation, promoting blood circulation and detoxifying. It is clinically used to treat colds, food accumulation, bruises, snake bites, urticaria, etc. There are related records in Chinese medicine literature that Artemisia striata enters the heart, liver, and lung meridians. In traditional Chinese medicine, meridians usually refer to the location of the drug's action, and the effect on specific diseases needs to be specifically demonstrated.

[0004] Inflammatory lung disease is a common disease in veterinary clinics. It is mainly caused by dust particles, harmful gases and pathogens in the air entering the lungs, which can cause coughing, dyspnea, persistent fever and continuous weight loss. While causing lung inflammation, it will further develop aggravating diseases such as pulmonary fibrosis, and eventually cause animal death. Clinical treatment of inflammatory lung diseases often uses antibiotics such as florfenicol, gentamicin and tilmicosin, but long-term use of antibiotics can cause the emergence of drug-resistant bacteria. At the same time, the large-scale use of antibiotics for treatment, due to excessive burden and damage to the liver and kidneys, causes hepatomegaly and lower limb edema, further harms the livestock and poultry body, and has great side effects. With the increasing requirements for "antibiotic reduction and replacement" in livestock and poultry breeding and treatment, there is a situation where no medicine is available. Therefore, it is increasingly important to develop Chinese veterinary medicines to replace antibiotics for the prevention and treatment of lung inflammation. Summary of the invention

[0005] The purpose of the present application is to provide the use of an Artemisia striata extract in the preparation of a drug for preventing and treating lung diseases. The drug effect of the Artemisia striata extract was experimentally verified by constructing a mouse model, indicating the use of the Artemisia striata extract in the preparation of a drug for preventing and treating lung diseases.

[0006] The present application relates to the use of an Artemisia sphaerocephala extract in the preparation of a drug for preventing and treating lung diseases. The Artemisia sphaerocephala extract is prepared using Artemisia sphaerocephala as a raw material, and the crude drug concentration is 20 to 110 mg / mL.

[0007] Preferably, the Artemisia argyi extract has a crude drug concentration of 50-55 mg / mL and is used to prepare a drug for preventing and treating lung inflammation.

[0008] Preferably, the Artemisia argyi extract has a crude drug concentration of 25 to 27.5 mg / mL and is used to prepare a drug for preventing and treating pulmonary fibrosis.

[0009] Specifically, the Artemisia annua extract contains sesquiterpenes, flavonoids, organic acids and phenylpropanoid chemical components, such as artemisinic acid, flavonoids, aflatoxin, montana glycoside, chlorogenic acid, tectorius glycoside, quinic acid, isochlorogenic acid A, luteolin, 7-hydroxycoumarin, ambroxan acid, isochlorogenic acid C, L-malic acid, tectorius flavonoids and sinomenine.

[0010] Specifically, the drug is a veterinary drug.

[0011] Specifically, the lung diseases include allergic pneumonia, pulmonary fibrosis or other diseases caused by damage to lung tissue, which can be caused by dust particles, harmful gases and pathogens. Dust particles, harmful gases or pathogens (such as Klebsiella pneumoniae) enter the lungs through the respiratory tract, causing high fever, weight loss, coughing and dyspnea in livestock and poultry, causing lung inflammation and pulmonary fibrosis. This application does not involve viral pneumonia.

[0012] Specifically, the dosage form of the drug for preventing and treating pulmonary inflammatory diseases is a pharmaceutically acceptable dosage form, which is an oral liquid, powder, tablet, granule, capsule, pill, syrup, suspension or emulsion.

[0013] Specifically, the preparation method of the powder comprises preparing the Artemisia argyi extract into an extract, and then freeze-drying the extract to prepare a freeze-dried powder.

[0014] Specifically, the preparation method of the Artemisia striata extract comprises removing the roots of the Artemisia striata, crushing, extracting by heating and refluxing with ethanol, combining the extracts and filtering to obtain the Artemisia striata extract. The main components of the whole plant of Artemisia striata are different from the main components of the aerial parts of Artemisia striata. According to research, the characteristic active ingredients of Artemisia striata are highest in flowers, and decrease in leaves, branches, stems and roots in turn. At the same time, the content of flavonoids and sesquiterpenoid compounds in flowers and leaves is relatively high. In the present application, the roots of Artemisia striata are removed and the aerial parts of Artemisia striata are selected.

[0015] Specifically, the ethanol concentration is 70% to 80%, the ratio of the ethanol to the Artemisia selengensis is 10 to 20 mL / mg, and the heating temperature is 80° C. to 90° C.

[0016] The present application also relates to a medicine for preventing and treating lung diseases, which has the sesquiterpenes, flavonoids, organic acids and phenylpropanoid chemical components involved in the extract in the above application as main components,

[0017] Among them, the mass ratio of sesquiterpenes, flavonoids, organic acids and phenylpropanoid chemical components is (3.5-4.5): (3.5-4.5): (0.5-1.5): (0.5-1.5).

[0018] Specifically, the lung diseases include hypersensitivity pneumonitis, pulmonary fibrosis or other diseases caused by damage to lung tissue.

[0019] Beneficial effects of this application:

[0020] First, this application clarifies the preventive and therapeutic effects of Artemisia striata extract on lung diseases. When applied, Artemisia striata extract is used in small dosages and has high efficacy. It can reduce the significant weight loss of livestock and poultry due to lung tissue damage, and has good anti-pneumonia and anti-pulmonary fibrosis activity. In addition, this application uses Artemisia striata as raw material, which is naturally sourced and has low cost. In veterinary clinical practice, this application effectively makes up for the shortcomings in the field, gives full play to the advantages of traditional Chinese veterinary products, and has positive significance for the prevention and treatment of livestock and poultry lung diseases.

[0021] Second, the drugs used in this application do not cause damage to livestock and poultry organs and have no side effects, which is a great advantage over existing antibiotic drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 This is the UHPLC-(+)ESI-MS spectrum of the Artemisia annua extract in Example 1.

[0023] Figure 2 This is the UHPLC-(-)ESI-MS spectrum of the Artemisia annua extract in Example 1.

[0024] Figure 3 The figure shows the changes in body weight of mice in each test group in Example 2.

[0025] Figure 4 This is the H&E staining result of lung tissue pathological section in Example 3.

[0026] Figure 5 This is Example 3, in which Elisa was used to detect the expression of inflammatory factors in alveolar lavage fluid.

[0027] Figure 6 The distribution of collagen in the Masson-stained lung tissue pathological sections of Example 4 is shown.

[0028] Figure 7 This is the expression of α-SMA protein (green) and Collagen I (red) protein detected by immunofluorescence in lung tissue in Example 4. DETAILED DESCRIPTION

[0029] The embodiments of the present application will be described in detail below in conjunction with the examples, but it will be appreciated by those skilled in the art that the following examples are only used to illustrate the present application and should not be considered as limiting the scope of the present application. In the examples, if specific conditions are not specified, they are carried out according to normal conditions or the conditions recommended by the manufacturer. If the manufacturer is not specified for the reagents or instruments used, they are all conventional products that can be obtained commercially.

[0030] The present application relates to the use of an Artemisia striata extract in the preparation of a drug for preventing and treating lung diseases, wherein the Artemisia striata extract is prepared using Artemisia striata as a raw material, and the crude drug concentration is 20 to 110 mg / mL, specifically 25 mg / mL, 50 mg / mL or 100 mg / mL, etc. If the crude drug concentration is lower than 20 mg / mL, the content of the active ingredient therein is too low, affecting the prevention and treatment effect.

[0031] The preparation method of the Artemisia striata extract comprises the following steps: removing the roots of the Artemisia striata in full bloom and retaining only the aerial parts; crushing the Artemisia striata into segments, and extracting the segments by heating and refluxing with 70% to 80% ethanol, wherein the ratio of ethanol to Artemisia striata is 10 to 20 mL / mg, that is, 10 to 20 mL of ethanol is used for every mg of Artemisia striata; combining the extracts and filtering to obtain the Artemisia striata extract.

[0032] Specifically, the heating temperature is 80° C. to 90° C., and the heating reflux extraction is performed at least twice.

[0033] The preparation method of the powder of Artemisia rapa extract comprises the following steps: concentrating the Artemisia rapa extract by rotary evaporation to prepare an extract, and then freeze-drying the extract by a freeze dryer to prepare a freeze-dried powder.

[0034] Example 1: Preparation of Artemisia argyi extract and powder

[0035] 1. The Artemisia argyi plants in full bloom were collected from the Barkol grassland in Hami area of ​​Xinjiang Uygur Autonomous Region, and their origin was identified by the Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences.

[0036] 2. Remove the roots of the whole herb of Artemisia striata and keep only the aerial part, which weighs 100g. Cut the aerial part into 5cm small segments and heat and reflux extract according to the ratio of drug weight (g): 80% ethanol volume (mL) of 1:10. Heat to 80℃ and extract by condensation reflux for 3 times, each time for 2h. Combine the extracts and filter through filter paper using a suction pump to obtain 3000mL of Artemisia striata extract with a crude drug concentration of 33mg / mL.

[0037] 3. Heat the Artemisia argyi extract at 45°C, use a rotary evaporator to concentrate it to 1g / mL of extract, and then freeze-dry it into powder using a freeze dryer.

[0038] Identification of main chemical components:

[0039] 1. Test methods

[0040] Sample processing method: Take the freeze-dried powder sample of Artemisia argyi extract, add 1mL 80% methanol to prepare a 10mg / ml sample solution, mix it by ultrasonic for 10min, and centrifuge it for 10min (14000r / min). Take 0.8mL of the supernatant and place it in a centrifuge tube, and centrifuge it again for 10min (14000r / min). Finally, take the supernatant and filter it through a 0.22μm filter membrane for inspection.

[0041] Chromatographic conditions: ACQUITY UPLC HSS T3 column (100 mm×2.1 mm, 1.8 μm, Waters Company); A (deionized water, containing 0.1% formic acid), B (acetonitrile, containing 0.1% formic acid) as mobile phases; flow rate of 0.2 mL / min, injection volume of 10 μL, column temperature of 35°C; elution gradient: 0-10 min, 100%-70% A; 10-25 min, 70%-60% A; 25-30 min, 60%-50% A; 30-40 min, 50%-30% A; 40-45 min, 30%-0% A; 45-60 min, 0% A; 60-60.5 min, 100% A; 60.5-70 min, 100% A.

[0042] Mass spectrometry conditions: heated electrospray ionization source (HESI); positive and negative ion detection modes; full scan scan mode; scan range: m / z 100-1500; MS1 resolution: 70000, MS2 resolution 17500; spray voltage: 3.2KV (positive ion mode), -3.0KV (negative ion mode); sheath gas flow rate: 40L / min; auxiliary gas: 15L / min; ion source temperature: 320℃ (positive ion mode), 350℃ (negative ion mode).

[0043] Data processing: After obtaining the UHPLC-(±)ESI-MS spectra in positive and negative ion detection modes, Compounddiscover 3.3 software was used to extract the mass spectrum characteristic peaks of the raw data (.raw format). The mass deviations of characteristic peak element matching, molecular formula prediction, and isotope distribution matching were all set to within 5 ppm. The mzcloud online database and the local mzVault Chinese medicine natural product database were used for characteristic peak identification. The screening criteria were mass deviation <5 ppm, consistent with isotope distribution, and mzVault best match database matching score >70 points.

[0044] 2. Test results

[0045] The positive ion TIC graph and negative ion TIC graph of the compound were obtained by LC-MS detection. The results are as follows: Figure 1 and Figure 2 As shown in Figure 2, the chemical components of Artemisia striata extract were mainly sesquiterpenes, flavonoids, organic acids and phenylpropanoids through the analysis of positive and negative ion TIC images.

[0046] The main compounds in the extract of Artemisia truncatum according to the peak area are: artemisinic acid, scutellariae, aflatin, mongoside, chlorogenic acid, tectorius glycoside, quinic acid, isochlorogenic acid A, luteolin, 7-hydroxycoumarin, ragweed acid, isochlorogenic acid C, L-malic acid, tectorius flavonoids and scutellariae, and the specific results are shown in Table 1. Among them, sesquiterpenes include artemisinic acid and ragweed acid; flavonoids include scutellariae, aflatin, aflatin, tectorius glycoside, luteolin, tectorius flavonoids, and scutellariae; organic acids include chlorogenic acid, quinic acid, isochlorogenic acid A, and L-malic acid; phenylpropanoids include 7-hydroxycoumarin and isochlorogenic acid C.

[0047] Table 1 Main chemical components of Artemisia scoparia extract

[0048]

[0049] Example 2: Effects of Artemisia truncatula extract on pulmonary inflammatory diseases

[0050] 1. Test methods

[0051] Establishment of mouse model of pulmonary inflammatory disease: C57BL / 6 mice weighing 20-22g and aged 6-8 weeks were taken. They were divided into 5 groups, 7 mice in each group. The experimental groups were: normal group (Nomal control group, NC); pulmonary inflammation control group (Cigarettesmoke group, CS); low dose group of Artemisia striata (Low dose group, L); middle dose group of Artemisia striata (Middledose group, M); high dose group of Artemisia striata (High dose group, H). The CS group, L group, M group and H group were stimulated by cigarette smoke to construct a pulmonary inflammation model in mice. 1 hour before each smoking, the CS group was given normal saline, the L group was given 125 mg / kg of the freeze-dried powder of Artemisia striata extract prepared in Example 1, the M group was given 250 mg / kg of the freeze-dried powder of Artemisia striata extract prepared in Example 1, and the H group was given 500 mg / kg of the freeze-dried powder of Artemisia striata extract prepared in Example 1. Each group of mice was placed in a 30L sealed container, and smoke was pumped into the container using a peristaltic pump. The fumigation process was as follows: the peristaltic pump drew a cigarette into the container for 1 minute, the mice were fumigated for 5 minutes, and the lid was opened to rest for 1 minute. Each group of mice cycled 12 cigarettes continuously, once a day, 6 days a week, for a total of 10 weeks.

[0052] 2. Test results

[0053] like Figure 3 As shown in the results, the body weight of mice in the CS group was significantly reduced compared with that in the NC group (P < 0.05). The body weight of mice in the M and H groups, which were given Artemisia striata extract in advance, was significantly increased compared with that in the CS group (P < 0.05).

[0054] 3. Test Conclusion

[0055] Under the stimulation of cigarette smoke, pulmonary inflammatory diseases are induced by smoke. From week 0 to week 10, the weight gain of CS group, L group, M group and H group was significantly lower than that of NC group. From week 3 to week 10, the weight gain of mice in group M and H group was significantly higher than that in group CS, indicating that Artemisia striata extract has a certain preventive and therapeutic effect on pulmonary inflammatory diseases. The weight of mice is generally calculated to be 20-22g, and the gavage volume of mice is 100μL. The Artemisia striata extract, with a crude drug concentration of 20-110mg / mL, is used to prepare drugs for the prevention and treatment of pulmonary inflammatory diseases.

[0056] Example 3: Inhibitory effect of Artemisia rapa extract on inflammation in lung tissue

[0057] 1. Test methods

[0058] (1) Observation of pathological sections by hematoxylin and eosin (H&E) staining: The mouse model of pulmonary inflammatory disease was the same as in Example 2. After 10 weeks, the lung tissues of mice in different groups were taken and fixed with 10% formaldehyde solution. After fixation, they were embedded in paraffin and cut into 4 μm slices. After dewaxing, the slices were stained with H&E. After sealing with neutral gum, the results were observed under a microscope.

[0059] (2) Detection of IL-1β, IL-6 and TNF-a inflammatory factor secretion: After the mice were anesthetized with Shutai 50, PBS was intubated to flush the mouse alveoli and trachea. 500 μL PBS was injected each time and extracted 3 times. The above operation was repeated 3 times, and the alveolar lavage fluid was combined and centrifuged, and the supernatant was collected for examination. ELISA was used to detect the content of IL-1β, IL-6 and TNF-a inflammatory factors in the supernatant.

[0060] 2. Test results

[0061] like Figure 4 As shown in the results, the CS group mice had inflammatory cell infiltration and bronchial closure in the lung tissue, and compared with the NC group, there was obvious lung inflammation. Compared with the CS group, the inflammatory cells in the lung tissue of the L, M and H groups of mice that were given Artemisia striata extract in advance were reduced.

[0062] like Figure 5As shown in the results, compared with the NC group, the inflammatory factors IL-1β, IL-6 and TNF-a in the bronchoalveolar lavage fluid of the CS group mice increased significantly (P < 0.05). Compared with the CS group, the secretion of IL-1β, IL-6 and TNF-a in the bronchoalveolar lavage fluid of the L group, M group and H group mice given Artemisia striata extract in advance was significantly reduced (P < 0.05). Among them, the L group and M group had the best effect in inhibiting lung inflammation.

[0063] 3. Test Conclusion

[0064] The Artemisia striata extract effectively prevents and treats the increase of inflammatory cells in the lung tissue of mice induced by cigarette smoke, reduces the secretion of inflammatory factors in the alveoli, and has a significant effect in preventing and treating lung inflammation. The weight of the mouse is generally 20 to 22 g, the volume of the mouse gavage is 100 μL, and the Artemisia striata extract has a crude drug concentration of 50 to 55 mg / mL, which is used to prepare a drug for preventing and treating lung inflammation.

[0065] Example 4: Inhibitory effect of Artemisia rapa extract on fibrosis in lung tissue

[0066] 1. Test methods

[0067] (1) Masson trichrome staining observation of pathological sections: The mouse model of pulmonary inflammatory disease was the same as in Example 2. After 10 weeks, the lung tissues of mice in different groups were taken and fixed with 10% formaldehyde solution. After fixation, they were embedded in paraffin and cut into 4 μm slices. After dewaxing, the slices were stained with Masson trichrome kit. After sealing with neutral gum, the distribution of collagen in the lung tissues of mice in each group was observed under a microscope.

[0068] (2) Immunofluorescence detection of a-SMA protein and Collagen I protein expression in lung tissue: Dehydrate the lung tissue samples to make them transparent and embed them in paraffin. Then dewax and bake the embedded samples. Then perform antigen retrieval, permeabilization and blocking. Prepare α-SMA primary antibody (dilution ratio of 1:100) and Collagen I primary antibody (dilution ratio of 1:200) in advance, add the diluted primary antibody to the sample and incubate overnight. After washing with PBS, add immunofluorescence secondary antibody and incubate in the dark for 1 hour. After washing with PBS, incubate with DAPI. After washing, seal the slides and observe the results under a fluorescence microscope.

[0069] 2. Test results

[0070] like Figure 6As shown in the results, the blue-stained collagen around the lung bronchi of mice in the CS group increased significantly compared with the NC group under the stimulation of cigarette smoke. Compared with the CS group, the blue-stained collagen around the lung bronchi of mice in the L, M and H groups that were given Artemisia striata extract in advance was significantly reduced. Among them, the M group had the best effect in inhibiting the expression of collagen around the lung bronchi. Figure 7 As shown in the figure, the experimental results showed that Collagen I protein is a type of collagen, and α-SMA protein is a characteristic protein of fibrosis. Compared with the NC group, the expression of green-stained α-SMA protein around the lung bronchi of mice in the CS group was significantly increased (P < 0.05). Compared with the NC group, the expression of red-stained Collagen I protein in the lung tissue of mice in the CS group was significantly increased (P < 0.05). Compared with the CS group, the expression of green-stained α-SMA protein around the lung bronchi of mice in the L, M and H groups that were pre-administered with Artemisia striata extract was significantly reduced (P < 0.05); at the same time, compared with the CS group, the expression of red-stained Collagen I protein in the lung tissue of mice was significantly reduced (P < 0.05). Among them, the L and M groups had a better effect in inhibiting the increase of α-SMA protein and Collagen I protein expression.

[0071] 3. Test Conclusion

[0072] The Artemisia striata extract effectively prevents and treats the increased expression of collagen in the lung tissue and around the lung bronchus of mice with pulmonary inflammation induced by cigarette smoke, and alleviates pulmonary fibrosis caused by pulmonary inflammatory diseases. The weight of the mouse is generally 20 to 22 g, the volume of the mouse gavage is 100 uL, and the Artemisia striata extract has a crude drug concentration of 25 to 27.5 mg / mL, which is used to prepare a drug for preventing and treating pulmonary fibrosis.

[0073] The veterinary medicine Shuanghuanglian Granules in the prior art (purchased from Shandong Yundafei Biotechnology Co., Ltd.) mainly consists of raw materials: Scutellaria baicalensis extract, honeysuckle, sucrose, dextrin, etc. In the research report, a pneumonia model was constructed by Mycoplasma pneumoniae. Treatment with 0.6g / kg, 1.2g / kg and 2.4g / kg Shuanghuanglian Granules can effectively relieve lung inflammation and inhibit the expression of IL-1β, IL-6 and TNF-a inflammatory factors caused by Mycoplasma pneumoniae. The Xinjiang Artemisia argyi extract can effectively prevent and treat lung inflammation, and the dosage is significantly reduced.

[0074] Although the present application has been described in detail above with general instructions and specific implementation methods, it is obvious to those skilled in the art that some modifications or improvements may be made to the present application based on the present application.

Claims

1. The use of an Artemisia affine extract in the preparation of a drug for preventing and treating lung diseases, characterized in that: The Artemisia striata extract is prepared by taking Artemisia striata as a raw material, and the crude drug concentration is 20-110 mg / mL.

2. The use of the Artemisia rapa extract according to claim 1 in the preparation of a drug for preventing and treating lung diseases, characterized in that: The Artemisia rapa extract contains sesquiterpenes, flavonoids, organic acids and phenylpropanoid chemical components.

3. The use of the Artemisia limbulata extract according to claim 1 in the preparation of a drug for preventing and treating lung diseases, characterized in that: The drug is a veterinary drug.

4. The use of the Artemisia limbulata extract according to claim 1 in preparing a drug for preventing and treating lung diseases, characterized in that: The lung diseases include hypersensitivity pneumonitis, pulmonary fibrosis or other diseases caused by damage to lung tissue.

5. Use of the Artemisia affine extract according to claim 1 in preparing a drug for preventing and treating lung diseases, characterized in that: The dosage form of the medicine for preventing and treating lung diseases is a pharmaceutically acceptable dosage form, and the pharmaceutically acceptable dosage form is oral liquid, powder, tablet, granule, capsule, pill, syrup, suspension or emulsion.

6. Use of the Artemisia affine extract according to claim 5 in preparing a drug for preventing and treating lung diseases, characterized in that: The preparation method of the powder comprises the steps of preparing the Artemisia rapa extract into an extract, and then freeze-drying the extract to prepare a freeze-dried powder.

7. Use of the Artemisia limbii extract according to claim 1 in preparing a drug for preventing and treating lung diseases, characterized in that: The preparation method of the Artemisia truncatum extract comprises the steps of preferably removing the root of the Artemisia truncatum, crushing the Artemisia truncatum, extracting the Artemisia truncatum by heating and refluxing with ethanol, combining the extracts and filtering to obtain the Artemisia truncatum extract.

8. Use of the Artemisia affine extract according to claim 7 in preparing a drug for preventing and treating lung diseases, characterized in that: The ethanol concentration is 70% to 80%, the ratio of the ethanol to the Artemisia selengensis is 10 to 20 mL / mg, and the heating temperature is 80° C. to 90° C.

9. A drug for preventing and treating lung diseases, characterized in that: The main components of the extract are sesquiterpenes, flavonoids, organic acids and phenylpropanoids. Among them, the mass ratio of sesquiterpenes, flavonoids, organic acids and phenylpropanoid chemical components is (3.5-4.5): (3.5-4.5): (0.5-1.5): (0.5-1.5).

10. A medicine for preventing and treating lung diseases according to claim 9, characterized in that: The lung diseases include hypersensitivity pneumonitis, pulmonary fibrosis or other diseases caused by damage to lung tissue.

Images